BioNTech Shares Advance Despite Clinical Trial Halt

BioNTech shares gain as a key US vaccine trial is halted due to recruitment issues, creating a data gap for fall boosters and shifting investor focus to its cancer pipeline.

In a notable market development, shares of BioNTech moved higher following the announcement that a key U.S. clinical trial for its updated COVID-19 vaccine has been terminated. The study, conducted in partnership with Pfizer and targeting adults aged 50 to 64, was halted not due to safety concerns but because of significant difficulties in enrolling enough participants.

Regulatory Hurdles Hinder Enrollment

The core challenge stemmed from stringent regulatory requirements set by the U.S. Food and Drug Administration (FDA). For vaccine authorization in the 50-64 age bracket, the FDA mandated large, placebo-controlled trials involving exclusively healthy adults—specifically excluding individuals with chronic conditions like hypertension or diabetes. A representative from a contract research organization involved described this cohort as "extremely difficult to recruit," noting that over 80% of interested candidates failed the initial health screening.

The trial aimed to enroll between 25,000 and 30,000 individuals. Enrollment officially closed on March 6, and monitoring for COVID-19 symptoms among all participants will cease on April 3. Pfizer and BioNTech have formally notified the FDA of their decision to stop the study.

A Data Gap Emerges for Fall Recommendations

The timing creates a significant data gap. The FDA's vaccine advisory committee is scheduled to meet in May to recommend strain selection for the fall vaccination campaign based on clinical study evidence. The absence of data from this discontinued trial removes a central pillar of evidence. Former FDA chief scientist Jesse Goodman stated plainly that without this data, a presentation to the committee is unlikely, and without that presentation, a specific authorization for this age group may not be granted.

Currently, neither BioNTech's Comirnaty nor Moderna's Spikevax possesses full FDA approval for healthy adults between 50 and 64 years old. Both vaccines are approved for individuals aged 65 and older, as well as for younger high-risk patients. Adding to the regulatory uncertainty, FDA vaccine chief Vinay Prasad, who advocated for the stricter trial requirements, is leaving the agency this month. Moderna is conducting a comparable trial targeting 30,000 participants and is reportedly facing identical recruitment challenges, according to insiders.

Market Focus Shifts to Oncology Pipeline

The positive market reaction underscores a broader shift in perspective. The commercial potential for the 50-64 demographic was already considered uncertain. BioNTech had previously forecast declining Comirnaty revenues for 2026, citing evolving vaccination recommendations and the transition from multi-year government contracts to the private market.

The investment narrative for BioNTech is now firmly centered on its oncology ambitions. The company currently has nine Phase III trials underway in cancer therapeutics, with six more slated to begin in 2026, which would bring the total number of active Phase III programs to fifteen. A co-development deal with Bristol Myers Squibb for the asset pumitamig, signed in June 2025 and valued at approximately $11 billion, is viewed as a cornerstone of this strategic transformation. With roughly €17.2 billion in cash and securities at the end of 2025, BioNTech possesses ample capital to fund its evolution from a pandemic beneficiary to a fully-fledged oncology company.